Evaluation of dosing strategy for pembrolizumab for oncology indications. - Wikidata - wikimedia - TriplyDB

Evaluation of dosing strategy for pembrolizumab for oncology indications.

Evaluation of dosing strategy for pembrolizumab for oncology indications.

http://www.wikidata.org/entity/Q38779793

about

Fixed Dosing of Monoclonal Antibodies in Oncology.Population Pharmacokinetics of Durvalumab in Cancer Patients and Association with Longitudinal Biomarkers of Disease Status.Pembrolizumab in the treatment of advanced urothelial cancer.Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.Pembrolizumab for the treatment of bladder cancer.Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed.Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology

P2860

Q38654371-71682C6B-41D1-43E7-A72D-DD7145284864 Q47291273-F3AC7D35-42D5-48C7-A1C8-A0079E3C57C4 Q47345366-9CF16CA4-6A10-4EDA-9ED2-DE3AF9AE5C9D Q47864236-0483FFEA-FDF1-4EBE-BC37-08E95AED65D7 Q47943881-B32447B5-9D32-4813-A1F0-107B36E7B458 Q49036770-6FACD6B1-934F-4C98-A61D-5A2E6AED70F4 Q49333794-F4F19FF7-249B-48E1-9E06-3E610302F390 Q49959323-84897928-61B9-4C0C-B753-471415030168 Q51804722-DA214E47-416C-41A8-AAB3-330859A28DE3 Q52721221-04B00E47-FBDD-42A0-98C7-3F6DD81F1AF1 Q55284597-C5A019EE-E005-421D-9392-A33AF2055392 Q55386599-54B23F85-0C8B-4242-BC4A-0A28169F7387 Q57214474-054C3105-B363-4C4A-8D5F-792451D00AD0 Q57483927-549C1B6F-4B8C-46A5-AEF1-EF03810A3CD2 Q57495826-B115506A-20AB-4013-8B77-9597DAFF3497

P2860

Evaluation of dosing strategy for pembrolizumab for oncology indications.

http://www.wikidata.org/entity/Q38779793

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Evaluation of dosing strategy for pembrolizumab for oncology indications.

@en

type

label

Evaluation of dosing strategy for pembrolizumab for oncology indications.

@en

prefLabel

Evaluation of dosing strategy for pembrolizumab for oncology indications.

@en

P1433

Q38779793-BE5C79CB-4F67-47AB-B3C4-0FB145D6E091

P1476

Q38779793-633B638C-935E-42E8-9E73-40AC643A3372

P2093

Q38779793-169F00DF-B7D9-41B5-AC4C-F69239DDE54D

Q38779793-1FAEEC51-DECF-43FE-9D95-13126D90BBB2

Q38779793-24A3F24E-CAB4-4706-ACCE-F1F7EFC5C0A5

Q38779793-6B4F4FB3-6B5C-4AA7-B17B-85CD5E87208B

Q38779793-73BC4F3E-C1F6-4A3D-B599-50804DFE01E0

Q38779793-9AAB15BE-99DE-4445-9905-F2D0E8C07B07

Q38779793-A5C658E2-1E80-407B-87C2-E6E23775818A

P2860

Q38779793-0E29F37E-4DE7-4DA0-9BA2-D865C9A7739E

Q38779793-0FBA86C1-0163-4732-A104-CE8C13EB94BA

Q38779793-18F4DFB8-472B-4EC3-BF66-D3F9FD777555

Q38779793-229B2A60-BD5F-4663-8785-8CF500652094

Q38779793-2F3A04C8-D1C2-47F3-9D91-21A6E71E64B0

Q38779793-43B5BC07-FE02-4F27-A368-561A26B0DAB5

Q38779793-47ACAC38-5632-425E-AA26-68F6CE9231A3

Q38779793-50172632-6307-46C7-BA52-A666C52A779B

Q38779793-56160E4A-2A58-4ADA-88EF-C2662DA88D80

Q38779793-5E717785-8819-4DB3-80B1-7F8A765A9528

P2888

Q38779793-CDE4D5FA-2E2F-4E24-BE5C-AE6ABB761D63

P304

Q38779793-FB3A4366-EA9F-42CD-894E-A0D6E6B8C336

P31

Q38779793-13646BB9-76C8-4269-BD4A-8174620E7307

Q38779793-ef8a31b6-0fee-4cf9-9f4f-b2e922c58d1b

P356

Q38779793-370F6529-A3E1-4101-A453-8B8E57753A4B

P478

Q38779793-C081419C-730D-4432-9F77-7C56C538F5B6

P577

Q38779793-62D64728-C5A0-4119-A7F8-282F6E10FCDA

P6179

Q38779793-97DC89DA-30BD-4E10-ADFF-B6093261C505

P698

Q38779793-6A58C195-6AE5-452B-B844-C1E0FFD04564

P921

Q38779793-5BFABB97-20BE-4093-8508-9C1E33BEFD85

P932

Q38779793-07178546-569D-4828-A428-D3C6199B84CA

P356

S40425-017-0242-5

P1433

Journal for Immunotherapy of Cancer

P1476

Evaluation of dosing strategy for pembrolizumab for oncology indications.

@en

P2093

Anna Kondic

http://www.w3.org/2001/XMLSchema#string

Claire H Li

http://www.w3.org/2001/XMLSchema#string

Dinesh de Alwis

http://www.w3.org/2001/XMLSchema#string

Julie A Stone

http://www.w3.org/2001/XMLSchema#string

Malidi Ahamadi

http://www.w3.org/2001/XMLSchema#string

Rik de Greef

http://www.w3.org/2001/XMLSchema#string

Tomoko Freshwater

http://www.w3.org/2001/XMLSchema#string

P2860

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Pembrolizumab for the treatment of non-small-cell lung cancer

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.

Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma.

Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Population pharmacokinetics of therapeutic monoclonal antibodies.

A guide to rational dosing of monoclonal antibodies.

P2888

s40425-017-0242-5

P304

43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-017-0242-5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085379298

http://www.w3.org/2001/XMLSchema#string

P698

28515943

http://www.w3.org/2001/XMLSchema#string

P921

P932

5433037

http://www.w3.org/2001/XMLSchema#string